Loading...
XLON
AREC
Market cap25mUSD
Jul 22, Last price  
51.50GBP
1D
1.02%
1Q
30.26%
IPO
-79.55%
Name

Arecor Therapeutics PLC

Chart & Performance

D1W1MN
P/E
P/S
425.21
EPS
Div Yield, %
Shrs. gr., 5y
2.04%
Rev. gr., 5y
43.65%
Revenues
5m
+90.30%
1,350,046747,6721,890,9891,697,5931,158,0002,403,0004,573,000
Net income
-9m
L-7.62%
-1,119,247-2,435,308-2,189,529-2,752,367-6,169,000-9,260,000-8,554,000
CFO
-6m
L-45.82%
-492,571-2,504,792-458,803-1,856,642-5,450,000-10,780,000-5,841,000

Profile

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
IPO date
Jun 03, 2021
Employees
51
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122019‑052018‑052017‑05
Income
Revenues
4,573
90.30%
2,403
107.51%
Cost of revenue
14,890
14,506
Unusual Expense (Income)
NOPBT
(10,317)
(12,103)
NOPBT Margin
Operating Taxes
(347)
(1,282)
Tax Rate
NOPAT
(9,970)
(10,821)
Net income
(8,554)
-7.62%
(9,260)
50.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,000
BB yield
-8.64%
Debt
Debt current
118
202
Long-term debt
558
374
Deferred revenue
(496)
Other long-term liabilities
28
496
Net debt
(6,153)
(12,278)
Cash flow
Cash from operating activities
(5,841)
(10,780)
CAPEX
(151)
(345)
Cash from investing activities
6,520
(7,993)
Cash from financing activities
(180)
5,160
FCF
(8,821)
(12,418)
Balance
Cash
6,752
12,806
Long term investments
77
48
Excess cash
6,600
12,734
Stockholders' equity
(19,449)
(13,535)
Invested Capital
29,342
31,158
ROIC
ROCE
EV
Common stock shares outstanding
30,623
28,936
Price
1.83
-23.96%
2.40
-40.00%
Market cap
55,886
-19.53%
69,447
-24.62%
EV
49,733
57,169
EBITDA
(9,821)
(11,762)
EV/EBITDA
Interest
15
26
Interest/NOPBT